Peripheral Rotational Atherectomy

Peripheral rotational atherectomy uses a rotating or abrasive device to modify calcified or otherwise resistant atherosclerotic plaque in peripheral arteries, typically to improve lesion preparation before balloon angioplasty, drug-coated balloon treatment, or stent placement. Its relevance is greatest where severe calcification, long lesions, chronic total occlusions, or vessel compliance limit conventional endovascular treatment. Clinical value depends on appropriate patient selection, operator expertise, imaging, embolic protection practices, and access to complementary therapies.

Peripheral intervention is moving toward a more lesion-specific approach in which plaque modification precedes definitive therapy when calcium limits balloon expansion or device delivery. This shift is supported by better intravascular imaging, more specialized atherectomy platforms, improved crossing and support technologies, and greater emphasis on preserving future treatment options. At the same time, treatment decisions remain constrained by embolization risk, perforation, dissection, distal runoff, renal considerations, and the need to demonstrate durable clinical benefit rather than procedural success alone.

Artificial intelligence can support peripheral rotational atherectomy through automated analysis of angiographic and intravascular images, calcium-pattern recognition, lesion-length assessment, device selection support, and identification of procedural complications. In follow-up, algorithms may help detect restenosis or changes in limb perfusion from imaging and clinical records. These applications remain dependent on representative validation datasets, interoperable imaging systems, clinician oversight, cybersecurity, and clear accountability. AI should augment-not replace-vascular expertise and prospective clinical evidence.

North America combines advanced endovascular infrastructure, specialist expertise, and relatively broad access to complex peripheral devices, while reimbursement scrutiny encourages evidence-based utilization. Europe emphasizes multidisciplinary vascular care, guideline alignment, health-technology assessment, and variation between national systems. Asia-Pacific includes highly developed procedural centers alongside areas where imaging, trained operators, and device access remain uneven. Latin America is influenced by private-sector capacity, import requirements, and disparities in referral pathways. The Middle East is developing specialized cardiovascular hubs, particularly in well-resourced systems, while Africa faces pronounced gaps in diagnosis, interventional infrastructure, and specialist coverage. Across all regions, training, supply continuity, and post-procedure surveillance are central adoption determinants.

ASEAN markets differ substantially in reimbursement, hospital capability, regulatory maturity, and access to vascular specialists, making regional harmonization valuable but incomplete. BRICS members combine large and diverse patient populations with uneven infrastructure, domestic manufacturing capacity, and variable access to advanced imaging and atherectomy. The European Union benefits from shared regulatory principles but retains nationally distinct reimbursement and procurement processes. G7 systems generally have mature vascular services and strong evidence expectations, although cost-effectiveness and workforce pressures influence use. NATO members span highly developed and resource-constrained health systems, with resilience and supply-chain considerations becoming more important. GCC countries often possess concentrated, well-equipped tertiary centers but continue to build broader referral and follow-up networks.

Australia supports evidence-oriented vascular practice but must address geographic concentration of specialist services. Brazil has substantial clinical need alongside regional disparities in public and private access. Canada combines advanced centers with lengthy referral distances and provincial variation. China is expanding sophisticated endovascular capability while navigating regulatory, procurement, and regional access differences. France, Germany, Italy, and Spain operate within the European framework but differ in reimbursement, hospital organization, and adoption pathways. India has leading tertiary institutions alongside significant affordability and infrastructure gaps. Japan emphasizes careful procedural practice, aging-patient care, and regulatory evaluation. Mexico faces uneven access between major urban centers and other regions. Russia’s access and supply environment is shaped by domestic production, sanctions-related constraints, and regional variation. South Korea has advanced hospitals and strong technology capability, while the United Kingdom prioritizes evidence, centralized guidance, and resource-conscious service delivery. The United States has extensive specialist expertise and device availability, with utilization influenced by coverage rules, site-of-care economics, and clinical evidence.

Industry leaders should define clear clinical use cases centered on severe calcification, lesion preparation, limb preservation, and procedural efficiency rather than device novelty alone. They should invest in comparative evidence, standardized endpoints, long-term follow-up, and transparent reporting of embolization, perforation, reintervention, and limb outcomes. Training programs should combine simulation, imaging interpretation, complication management, and proctoring. Commercial and clinical teams should map country-specific regulatory and reimbursement requirements, strengthen distributor and service networks, and plan for supply continuity. Partnerships with hospitals can improve patient selection, referral pathways, registry participation, and post-procedure surveillance. AI-enabled tools should be introduced only with validated performance, human oversight, privacy safeguards, and workflows that reduce-not increase-clinical burden.

This executive summary is structured around the clinical function of peripheral rotational atherectomy and the factors that influence its adoption. A rigorous underlying assessment should triangulate peer-reviewed clinical studies, professional-society guidance, regulatory documents, health-technology assessments, hospital protocols, reimbursement policies, procedural registries, and interviews with qualified vascular specialists. Evidence should be screened for study design, population, lesion characteristics, comparator, follow-up duration, endpoint definitions, and conflict-of-interest disclosures. Regional, group, and country comparisons should account for differences in disease burden, infrastructure, referral patterns, reimbursement, regulation, and operator training. Conclusions should distinguish established evidence from emerging applications and avoid unsupported estimates or extrapolation.

Peripheral rotational atherectomy has a focused role in preparing difficult peripheral lesions when calcification or plaque burden limits conventional endovascular treatment. Its contribution is strongest when integrated with imaging, complementary devices, embolic-risk management, experienced operators, and structured follow-up. Regional and national conditions will continue to shape access and utilization, while AI may improve planning and surveillance if validated responsibly. Leaders who combine clinical evidence, workforce development, regulatory discipline, and reliable care pathways will be best positioned to translate procedural capability into durable patient benefit.